Dr. Maobin Meng 孟茂斌
Chief Physician, Associate Professor
Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: CyberKnife and intensity-modulated radiotherapy for thoracic, abdominal, pelvic, and head and neck tumors. Molecular targeted therapy and comprehensive cancer treatment.
Dr. Meng is a Chief Physician and Associate Professor specializing in clinical radiation oncology. A Clinical Level II Principal Investigator with GCP certification, Dr. Meng has led national and provincial research projects and participated in international multicenter clinical trials. Dr. Meng serves as a reviewer and editorial board member for several international radiation oncology journals.
Professional roles
- Reviewer and editorial board member for multiple international radiation oncology journals
Name order: in Chinese the family name comes first (Meng Maobin). Papers usually list the name as Maobin Meng or Meng M.
Selected publications
47 papers on PubMed matched by name and affiliation; 12 as first or senior author since 2016. Most recent first- or senior-author papers:
- Radiother Oncol, 2026 (senior author): Tumor control probability modeling of stereotactic radiosurgery and fractionated stereotactic radiosurgery for patients with brainstem metastases. PubMed 41734863
- Radiother Oncol, 2026 (senior author): Response to commentary on "Brachial plexopathy following stereotactic body radiation therapy in apical lung malignancies: A dosimetric pooled analysis of individual patient data" by Sawada et al. PubMed 41057082
- Front Immunol, 2025 (senior author): The efficacy and safety of neoadjuvant and adjuvant chemo(radio)therapy combined with surgery in patients with locally advanced rectal cancer harboring defective mismatch repair system: a large-scale multicenter propensity score analysis. PubMed 40692776
- Radiother Oncol, 2025 (senior author): Risk-adapted stereotactic body radiation therapy for the treatment of large (>3 cm) primary lung cancer with or without histologic confirmation: A propensity score matched and weighted analysis. PubMed 39933623
- Radiother Oncol, 2024 (senior author): Brachial plexopathy following stereotactic body radiation therapy in apical lung malignancies: A dosimetric pooled analysis of individual patient data. PubMed 39255923
- Radiother Oncol, 2023 (senior author): Reirradiation with stereotactic body radiotherapy for primary or secondary lung malignancies: Tumor control probability and safety analyses. PubMed 37480993
- Cancer Sci, 2022 (senior author): Risk-adapted stereotactic body radiotherapy for patients with cervical spinal metastases. PubMed 36056609
- Cancer Sci, 2019 (first author): Risk-adapted stereotactic body radiation therapy for central and ultra-central early-stage inoperable non-small cell lung cancer. PubMed 31464032
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion